# A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)

> **NCT07500207** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Changchun BCHT Biotechnology Co.** · enrollment: 3000 (estimated)

## Conditions studied

- Rabies Prevention

## Interventions

- **BIOLOGICAL:** Experimental Lyophilized Human Rabies Vaccine (Human Diploid Cell)
- **BIOLOGICAL:** approved Rabies vaccine

## Key facts

- **NCT ID:** NCT07500207
- **Lead sponsor:** Changchun BCHT Biotechnology Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-03-04
- **Primary completion:** 2026-05-25
- **Final completion:** 2027-03-25
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07500207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07500207, "A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07500207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*